A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
Study sponsor: Madrigal Pharmaceuticals, Inc. · MDGL
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2028-01Estimated
Enrollment · participants1759Actual
Source updated2026-06-01Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.